Literature DB >> 19248809

The therapeutic potential of novel cannabinoid receptors.

Faith R Kreitzer1, Nephi Stella.   

Abstract

Cannabinoids produce a plethora of biological effects, including the modulation of neuronal activity through the activation of CB(1) receptors and of immune responses through the activation of CB(2) receptors. The selective targeting of either of these two receptor subtypes has clear therapeutic value. Recent evidence indicates that some of the cannabinomimetic effects previously thought to be produced through CB(1) and/or CB(2) receptors, be they on neuronal activity, on the vasculature tone or immune responses, still persist despite the pharmacological blockade or genetic ablation of CB(1) and/or CB(2) receptors. This suggests that additional cannabinoid and cannabinoid-like receptors exist. Here we will review this evidence in the context of their therapeutic value and discuss their true belonging to the endocannabinoid signaling system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248809      PMCID: PMC3685492          DOI: 10.1016/j.pharmthera.2009.01.005

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  175 in total

Review 1.  Target validation of G-protein coupled receptors.

Authors:  Alan Wise; Katy Gearing; Stephen Rees
Journal:  Drug Discov Today       Date:  2002-02-15       Impact factor: 7.851

2.  6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

Authors:  Adèle Thomas; Ruth A Ross; Bijali Saha; Anu Mahadevan; Raj K Razdan; Roger G Pertwee
Journal:  Eur J Pharmacol       Date:  2004-03-08       Impact factor: 4.432

3.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

Authors:  G Griffin; P J Atkinson; V M Showalter; B R Martin; M E Abood
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  Cellular signal transduction by anandamide and 2-arachidonoylglycerol.

Authors:  A C Howlett; S Mukhopadhyay
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

Review 5.  PPAR-gamma: a nuclear receptor with affinity for cannabinoids.

Authors:  Sumner Burstein
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

6.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

Authors:  D Shire; B Calandra; M Rinaldi-Carmona; D Oustric; B Pessègue; O Bonnin-Cabanne; G Le Fur; D Caput; P Ferrara
Journal:  Biochim Biophys Acta       Date:  1996-06-07

7.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.

Authors:  V Abadji; S Lin; G Taha; G Griffin; L A Stevenson; R G Pertwee; A Makriyannis
Journal:  J Med Chem       Date:  1994-06-10       Impact factor: 7.446

Review 8.  Lysophospholipid receptors: signaling and biology.

Authors:  Isao Ishii; Nobuyuki Fukushima; Xiaoqin Ye; Jerold Chun
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

9.  The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Lesley A Ford; Ruth A Ross; Maria Waldhoer; Andrew J Irving
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  28 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

2.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors:  Giorgia Galiazzo; Fiorella Giancola; Agnese Stanzani; Federico Fracassi; Chiara Bernardini; Monica Forni; Marco Pietra; Roberto Chiocchetti
Journal:  Histochem Cell Biol       Date:  2018-06-07       Impact factor: 4.304

Review 4.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

5.  Comparative effects of chlorpyrifos in wild type and cannabinoid Cb1 receptor knockout mice.

Authors:  Praveena Baireddy; Jing Liu; Myron Hinsdale; Carey Pope
Journal:  Toxicol Appl Pharmacol       Date:  2011-06-13       Impact factor: 4.219

6.  Cannabinoid receptor agonists potentiate action potential-independent release of GABA in the dentate gyrus through a CB1 receptor-independent mechanism.

Authors:  Mackenzie E Hofmann; Chinki Bhatia; Charles J Frazier
Journal:  J Physiol       Date:  2011-06-06       Impact factor: 5.182

7.  The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.

Authors:  Rudolf Schicho; Mohammad Bashashati; Misha Bawa; Douglas McHugh; Dieter Saur; Huang-Ming Hu; Andreas Zimmer; Beat Lutz; Ken Mackie; Heather B Bradshaw; Donna-Marie McCafferty; Keith A Sharkey; Martin Storr
Journal:  Inflamm Bowel Dis       Date:  2010-11-15       Impact factor: 5.325

8.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

9.  A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats.

Authors:  Lin Li; Yihao Tao; Jun Tang; Qianwei Chen; Yang Yang; Zhou Feng; Yujie Chen; Liming Yang; Yunfeng Yang; Gang Zhu; Hua Feng; Zhi Chen
Journal:  Transl Stroke Res       Date:  2015-09-16       Impact factor: 6.829

Review 10.  Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

Authors:  Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.